Britain will begin to roll out Merck’s molnupiravir COVID-19 antiviral tablet via a drug trial later this month, Susan Hopkins, Chief Medical Adviser on the UK Well being Safety Company mentioned on Sunday.
Final week Britain turned the primary nation on the earth to approve the possibly game-changing COVID-19 antiviral tablet, collectively developed by U.S.-based Merck & Co Inc and Ridgeback Biotherapeutics.
Learn extra:
What are antiviral COVID-19 drugs and the way may they assist?
The federal government mentioned in October it had secured 480,000 programs of the Merck drug, in addition to 250,000 programs of an antiviral tablet developed by Pfizer Inc.
Requested concerning the molnupiravir approval, Hopkins instructed BBC tv: “That’s nice information and it’ll begin to be rolled out via a drug trial ultimately of this month/the start of December.”
Hopkins mentioned all of the trials up to now had been executed with the unvaccinated, so this might assist perceive the way it will work within the wider vaccinated inhabitants.
“The brand new Pfizer drug might be not going to be licensed till the brand new 12 months a while,” she added. “It’s nonetheless prone to be a few months away.”
(Reporting by Kylie MacLellan Modifying by Gareth Jones)
